United States - English - NLM (National Library of Medicine)

a-s medication solutions - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infarc

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine extended-release tablets are indicated for use as an anticonvulsant drug. evidence supporting efficacy of carbamazepine extended-release tablets as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvement than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by carbamazepine extended-release tablets (see precautions, general). carbamazepine extended-release tablets are indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. carbamazepine should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyclic compounds, such as amitriptyline, desipramine, imipramine, protriptyline, nortriptyline, etc. likewise, on theoretical grounds its use with monoamine oxidase (mao) inhibitors is not recommended. before administration of carbamazepine, mao inhibitors should be discontinued for a minimum of 14 days, or longer if the clinical situation permits. coadministration of carbamazepine and nefazodone may result in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect. coadministration of carbamazepine with nefazodone is contraindicated. no evidence of abuse potential has been associated with carbamazepine, nor is there evidence of psychological or physical dependence in humans.

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: zydus healthcare philippines, inc.; distributor: zydus healthcare philippines, inc. - atorvastatin (as calcium) - film-coated tablet - 10 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

healthcare pharmaceuticals ltd. - moxifloxacin - tablet - 400 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

dr-reddy -

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - injection - see ingredients - each 2,0 ml ampoule contains ranitidine hydrochloride equivalent to ranitidine 50,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains meloxicam 7,5 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains meloxicam 15,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains paroxetine hydrochloride equivalent to paroxetine 20,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - injection - see ingredients - each 2,0 ml ampoule contains tramadol hydrochloride 100,0 mg